Maat Pharma Aktie - MAAT

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Premium

Current Price

7,12

Gebot

7,10

Fragen

7,20

Volumen

1.002

7,12 Tagesbereich 7,26

6,52 52-Wochen-Bereich 9,96

Marktkapitalisierung

82,707M

Handelsende

7,20

Handelsbeginn

7,26

Letzte Trade

7.12

Letzter Handelszeitpunkt

09:31:27

Finanzvolumen

VWAP

Durchschnittliches Volumen (3 Mio.)

6.305

Ausgegebene Aktien

11.616.199

Dividendenrendite

Kurs-Gewinn-Verhältnis

0,00

Gewinn pro Aktie (EPS)

Erlöse

2,23M

Nettogewinn

-19,72M

Sektor

Pharmaceutical Preparations

Branche

Pharmaceutical Preparations

Website

www.maatpharma.com

Hauptsitz

Lyon, Rhone, Fra

Gegründet

Maat Pharma SA is listed in the Pharmaceutical Preparations sector of the Euronext with ticker MAAT. The last closing price for Maat Pharma was 7,20 €. Over the last year, Maat Pharma shares have traded in a share price range of 6,52 € to 9,96 €.

Maat Pharma currently has 11.616.199 shares in issue. The market capitalisation of Maat Pharma is 83,64 € million.

MaaT Pharma Announces Positive Second DSMB Review of Ongoing Phase 2b Clinical Trial Evaluating MaaT033 for Patients Receiving Allo-HSCT

The Independent Data Safety and Monitoring Board (DSMB) has recommended that the trial proceeds as planned without modification. Consistent good...

MaaT Pharma annonce des résultats positifs pour l'étude pivotale de Phase 3 ARES évaluant MaaT013 dans la maladie aiguë du greffon contre l'hôte

L'étude a atteint son critère principal d’évaluation avec un taux de réponse globale gastro-intestinale significatif au 28ème jour de 62...

MaaT Pharma: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital

Article 223-16 of the General Regulations of the Financial Markets Authority (AMF - Autorité des Marchés Financiers) Regulatory News: MaaT Pharma...

CORRECTING and REPLACING: MaaT Pharma Presented Positive Updated Data on MaaT013 in the Early Access Program at ASH 2024 Annual Meeting

MaaT Pharma to host a KOL webinar on December 17th, 2024, to discuss data and the unmet medical need in acute Graft-versus-Host Disease (aGvHD...

MaaT Pharma présente des données actualisées positives pour MaaT013 issues du programme d’accès compassionnel au Congrès Annuel 2024 de l’ASH

MaaT Pharma organise un webinaire avec des experts le 17 décembre 2024 pour détailler les données et échanger sur les besoins médicaux non...

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	-0.38	-5.06666666667	7.5	7.5	7.12	2708	7.29394092	DE
4	-0.98	-12.0987654321	8.1	8.46	7.12	4708	7.69806846	DE
12	-0.64	-8.24742268041	7.76	9.96	7.12	6305	8.18656189	DE
26	0	0	7.12	9.96	6.8	3731	8.02469775	DE
52	0.02	0.281690140845	7.1	9.96	6.52	2723	8.07526596	DE
156	-5.88	-45.2307692308	13	13.4	4.5	1540	8.14362784	DE
260	-6.38	-47.2592592593	13.5	14.4	4.5	1681	8.99160995	DE

MAAT - Frequently Asked Questions (FAQ)

What is the current Maat Pharma share price?

The current share price of Maat Pharma is 7,12 €

How many Maat Pharma shares are in issue?

Maat Pharma has 11.616.199 shares in issue

What is the market cap of Maat Pharma?

The market capitalisation of Maat Pharma is EUR 83,64M

What is the 1 year trading range for Maat Pharma share price?

Maat Pharma has traded in the range of 6,52 € to 9,96 € during the past year

What is the reporting currency for Maat Pharma?

Maat Pharma reports financial results in EUR

What is the latest annual turnover for Maat Pharma?

The latest annual turnover of Maat Pharma is EUR 2,23M

What is the latest annual profit for Maat Pharma?

The latest annual profit of Maat Pharma is EUR -19,72M

What is the registered address of Maat Pharma?

The registered address for Maat Pharma is 70 AVENUE TONY GARNIER, LYON, RHONE, 69007

What is the Maat Pharma website address?

The website address for Maat Pharma is www.maatpharma.com

Which industry sector does Maat Pharma operate in?

Maat Pharma operates in the PHARMACEUTICAL PREPARATIONS sector

Volumen
% Tops
% Flops

Symbol	Preis	Vol.
ALCYBCybergun	0,0002 € (100,00%)	23,15M
ALEUPEuroplasma	0,0158 € (56,44%)	12,54M
ALTMENoxxon Pharma NV	0,085 € (19,89%)	1,09M
YOUNIYounited Financial SA	15,50 € (19,23%)	130
BAIOdyssey Acquisition SA	0,25 € (19,05%)	46,64k
ALNEVNeovacs	0,1099 € (-12,08%)	4,1k
VACBSPierre & Vacances	0,0564 € (-11,88%)	5,13k
ALARFAdeunis	0,68 € (-9,33%)	3,62k
GNROGeNeuro SA	0,127 € (-9,29%)	46,95k
ALCABCabasse SA	1,78 € (-8,25%)	5,65k
ATOAtos SE	0,0028 € (3,70%)	925,26M
ALCYBCybergun	0,0002 € (100,00%)	23,15M
ALVERVergnet	0,0006 € (0,00%)	20,45M
ALEUPEuroplasma	0,0158 € (56,44%)	12,54M
BCPBanco Comercial Portugues SA	0,5388 € (1,20%)	9,88M

Foren

Foren anzeigen

Keine Diskussionen Gefunden.

Neuen Thread Erstellen

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Maat Pharma SA (MAAT)

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Wichtige Statistiken und Details

Über Maat Pharma SA

MAAT Neueste Nachrichten

MaaT Pharma Announces Positive Second DSMB Review of Ongoing Phase 2b Clinical Trial Evaluating MaaT033 for Patients Receiving Allo-HSCT

MaaT Pharma annonce des résultats positifs pour l'étude pivotale de Phase 3 ARES évaluant MaaT013 dans la maladie aiguë du greffon contre l'hôte

MaaT Pharma: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital

CORRECTING and REPLACING: MaaT Pharma Presented Positive Updated Data on MaaT013 in the Early Access Program at ASH 2024 Annual Meeting

MaaT Pharma présente des données actualisées positives pour MaaT013 issues du programme d’accès compassionnel au Congrès Annuel 2024 de l’ASH

MaaT Pharma Announces Positive Second DSMB Review of Ongoing Phase 2b Clinical Trial Evaluating MaaT033 for Patients Receiving Allo-HSCT

MaaT Pharma annonce des résultats positifs pour l'étude pivotale de Phase 3 ARES évaluant MaaT013 dans la maladie aiguë du greffon contre l'hôte

MaaT Pharma : Information mensuelle relative au nombre total de droits de vote et d'actions composant le capital social

CORRECTING and REPLACING: MaaT Pharma Presented Positive Updated Data on MaaT013 in the Early Access Program at ASH 2024 Annual Meeting

MaaT Pharma Presented Positive Updated Data on MaaT013 in the Early Access Program at ASH 2024 Annual Meeting

MaaT Pharma Announces First U.S. Patient Treated at City of Hope Under Single Patient Expanded Access for MaaT013 in Acute Graft-versus-Host Disease

MaaT Pharma Announces Positive Phase 1b Results, Meeting Primary Endpoint in the Evaluation of MaaT033 in Amyotrophic Lateral Sclerosis (ALS)

MaaT Pharma to Present Updates from Early Access Program at the 2024 ASH Annual Meeting Demonstrating Prolonged Long-Term Survival in Patients Receiving MaaT013 in aGvHD

MAAT - Frequently Asked Questions (FAQ)

Beweger

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Trends

Toplisten

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Maat Pharma SA (MAAT) Börsenkurse

Maat Pharma SA (MAAT)

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Wichtige Statistiken und Details

Über Maat Pharma SA

MAAT Neueste Nachrichten

MaaT Pharma Announces Positive Second DSMB Review of Ongoing Phase 2b Clinical Trial Evaluating MaaT033 for Patients Receiving Allo-HSCT

MaaT Pharma annonce des résultats positifs pour l'étude pivotale de Phase 3 ARES évaluant MaaT013 dans la maladie aiguë du greffon contre l'hôte

MaaT Pharma: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital

CORRECTING and REPLACING: MaaT Pharma Presented Positive Updated Data on MaaT013 in the Early Access Program at ASH 2024 Annual Meeting

MaaT Pharma présente des données actualisées positives pour MaaT013 issues du programme d’accès compassionnel au Congrès Annuel 2024 de l’ASH

MaaT Pharma Announces Positive Second DSMB Review of Ongoing Phase 2b Clinical Trial Evaluating MaaT033 for Patients Receiving Allo-HSCT

MaaT Pharma annonce des résultats positifs pour l'étude pivotale de Phase 3 ARES évaluant MaaT013 dans la maladie aiguë du greffon contre l'hôte

MaaT Pharma : Information mensuelle relative au nombre total de droits de vote et d'actions composant le capital social

CORRECTING and REPLACING: MaaT Pharma Presented Positive Updated Data on MaaT013 in the Early Access Program at ASH 2024 Annual Meeting

MaaT Pharma Presented Positive Updated Data on MaaT013 in the Early Access Program at ASH 2024 Annual Meeting

MaaT Pharma Announces First U.S. Patient Treated at City of Hope Under Single Patient Expanded Access for MaaT013 in Acute Graft-versus-Host Disease

MaaT Pharma Announces Positive Phase 1b Results, Meeting Primary Endpoint in the Evaluation of MaaT033 in Amyotrophic Lateral Sclerosis (ALS)

MaaT Pharma to Present Updates from Early Access Program at the 2024 ASH Annual Meeting Demonstrating Prolonged Long-Term Survival in Patients Receiving MaaT013 in aGvHD

MAAT - Frequently Asked Questions (FAQ)

Beweger

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Werbung entfernen